{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:02:04Z","timestamp":1794268924917,"version":"4.9.0"},"reference-count":336,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune disease, caused by unwanted immune responses to self-antigens, affects millions of people each year and poses a great social and economic burden to individuals and communities. In the course of autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes mellitus, and multiple sclerosis, disturbances in the balance between the immune response against harmful agents and tolerance towards self-antigens lead to an immune response against self-tissues. In recent years, various regulatory immune cells have been identified. Disruptions in the quality, quantity, and function of these cells have been implicated in autoimmune disease development. Therefore, targeting or engineering these cells is a promising therapeutic for different autoimmune diseases. Regulatory T cells, regulatory B cells, regulatory dendritic cells, myeloid suppressor cells, and some subsets of innate lymphoid cells are arising as important players among this class of cells. Here, we review the roles of each suppressive cell type in the immune system during homeostasis and in the development of autoimmunity. Moreover, we discuss the current and future therapeutic potential of each one of these cell types for autoimmune diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1075813","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T04:21:45Z","timestamp":1670991705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":92,"title":["The emerging role of regulatory cell-based therapy in autoimmune disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Farbod","family":"Ghobadinezhad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasim","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Mozaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheida","family":"Beiranvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehran","family":"Pournazari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Rezaei-Tazangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Khorram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"Afshinpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob A.","family":"Robino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Reza","family":"Aref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo M. R.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrg2489","article-title":"Detecting shared pathogenesis from the shared genetics of immune-related diseases","volume":"10","author":"Zhernakova","year":"2009","journal-title":"Nat Rev Genet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2012.05.002","article-title":"Epidemiology of environmental exposures and human autoimmune diseases: findings from a national institute of environmental health sciences expert panel workshop","volume":"39","author":"Miller","year":"2012","journal-title":"J Autoimmun"},{"key":"B3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1021\/acs.est.5b03709","article-title":"Ambient air pollution exposure estimation for the global burden of disease 2013","volume":"50","author":"Brauer","year":"2016","journal-title":"Environ Sci Technol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.autrev.2012.07.014","article-title":"New genetic interpretation of old diseases","volume":"12","author":"Touitou","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0041-4","article-title":"Next-generation regulatory T cell therapy","volume":"18","author":"Ferreira","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13287-022-02782-7","article-title":"Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases","volume":"13","author":"Jasim","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.autrev.2021.102931","article-title":"Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases","volume":"21","author":"Su","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0028-5","article-title":"Promises and limitations of immune cell-based therapies in neurological disorders","volume":"14","author":"Hu","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141623","article-title":"Regulatory T cells: mechanisms of differentiation and function","volume":"30","author":"Josefowicz","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.155.3.1151","article-title":"Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). breakdown of a single mechanism of self-tolerance causes various autoimmune diseases","volume":"155","author":"Sakaguchi","year":"1995","journal-title":"J Immunol"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.162.9.5317","article-title":"Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance","volume":"162","author":"Itoh","year":"1999","journal-title":"J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13011","article-title":"From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation","volume":"1417","author":"Bacchetta","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nri3155","article-title":"Selection of regulatory T cells in the thymus","volume":"12","author":"Hsieh","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B18","article-title":"Infectious immunological tolerance","volume":"21","author":"Gershon","year":"1971","journal-title":"Immunology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.8094901","article-title":"\u201cInfectious\u201d transplantation tolerance","volume":"259","author":"Qin","year":"1993","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.4.791","article-title":"Antigen-driven bystander suppression after oral administration of antigens","volume":"174","author":"Miller","year":"1991","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"102715","DOI":"10.1016\/j.autrev.2020.102715","article-title":"Regulatory T cell heterogeneity and therapy in autoimmune diseases","volume":"20","author":"Zhang","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/imr.12160","article-title":"tTregs, pTregs, and iTregs: similarities and differences","volume":"259","author":"Shevach","year":"2014","journal-title":"Immunol Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1084\/jem.179.2.493","article-title":"High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells","volume":"179","author":"Bacchetta","year":"1994","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12333","article-title":"Transplant tolerance to pancreatic islets is initiated in the graft and sustained in the spleen","volume":"13","author":"Gagliani","year":"2013","journal-title":"Am J Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.001","article-title":"The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases","volume":"49","author":"Roncarolo","year":"2018","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"eabf5264","DOI":"10.1126\/scitranslmed.abf5264","article-title":"Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients","volume":"13","author":"Chen","year":"2021","journal-title":"Sci Transl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2015.18","article-title":"Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease","volume":"16","author":"DuPage","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nri3464","article-title":"The plasticity and stability of regulatory T cells","volume":"13","author":"Sakaguchi","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-392324","article-title":"Functionally distinct subsets of human FOXP3+ treg cells that phenotypically mirror effector Th cells","volume":"119","author":"Duhen","year":"2012","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/ajt.14936","article-title":"Tailoring the homing capacity of human tregs for directed migration to sites of Th1-inflammation or intestinal regions","volume":"19","author":"Hoeppli","year":"2019","journal-title":"Am J Transplantation"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21404","article-title":"Subpopulations of T regulatory cells in blood stem cell harvests influence development of acute graft versus host disease in allogeneic transplant recipients","volume":"94","author":"Roschupkina","year":"2018","journal-title":"Cytometry Part B: Clin Cytometry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Dominguez-Villar","year":"2018","journal-title":"Nat Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101328","article-title":"Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells","volume":"187","author":"Wollenberg","year":"2011","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130604","article-title":"Follicular regulatory T cells control humoral autoimmunity via NFAT2-regulated CXCR5 expression","volume":"211","author":"Vaeth","year":"2014","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02704","article-title":"Control of the germinal center by follicular regulatory T cells during infection","volume":"9","author":"Miles","year":"2018","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141054","article-title":"Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals","volume":"130","author":"Gong","year":"2020","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0228-3","article-title":"Cell-based therapies with T regulatory cells","volume":"31","author":"Gliwi\u0144ski","year":"2017","journal-title":"BioDrugs"},{"key":"B38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/cei.13297","article-title":"Methods to manufacture regulatory T cells for cell therapy","volume":"197","author":"MacDonald","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/art.40737","article-title":"Adoptive treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall\u2019Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2016.12.003","article-title":"Expansion of human tregs from cryopreserved umbilical cord blood for GMP-compliant autologous adoptive cell transfer therapy","volume":"4","author":"Seay","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"305859","DOI":"10.1155\/2008\/305859","article-title":"Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood","volume":"2008","author":"Fujimaki","year":"2008","journal-title":"Clin Dev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/ajt.13456","article-title":"Discarded human thymus is a novel source of stable and long-lived therapeutic regulatory T cells","volume":"16","author":"Dijke","year":"2016","journal-title":"Am J Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3646","article-title":"Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment","volume":"18","author":"Kitagawa","year":"2017","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900733","article-title":"Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases","volume":"203","author":"Tahvildari","year":"2019","journal-title":"J Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344205","article-title":"Control of tissue-localized immune responses by human regulatory T cells","volume":"45","author":"Pesenacker","year":"2015","journal-title":"Eur J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxy051","article-title":"Producing proT cells to promote immunotherapies","volume":"30","author":"Singh","year":"2018","journal-title":"Int Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay6422","article-title":"Gene editing to induce FOXP3 expression in human CD4(+) T cells leads to a stable regulatory phenotype and function","volume":"12","author":"Honaker","year":"2020","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003219","article-title":"First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings","volume":"5","author":"MacMillan","year":"2021","journal-title":"Blood Adv"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood\u2013derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"J Am Soc Hematol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"J Am Soc Hematol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.exphem.2005.10.011","article-title":"Tolerance induction by third-party \u201coff-the-shelf\u201d CD4+CD25+ treg cells","volume":"34","author":"Steiner","year":"2006","journal-title":"Exp Hematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13113","article-title":"Sequential monitoring and stability of ex vivo-expanded autologous and nonautologous regulatory T cells following infusion in nonhuman primates","volume":"15","author":"Zhang","year":"2015","journal-title":"Am J Transplant"},{"key":"B55","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-Shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s00018-011-0907-z","article-title":"The battle against immunopathology: infectious tolerance mediated by regulatory T cells","volume":"69","author":"Gravano","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402861","article-title":"Donor requirements for regulatory T cell suppression of murine graft-versus-Host disease","volume":"195","author":"Pierini","year":"2015","journal-title":"J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3860","article-title":"HLA-e-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.106","article-title":"Translational implications for off-the-shelf immune cells expressing chimeric antigen receptors","volume":"24","author":"Torikai","year":"2016","journal-title":"Mol Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1097\/MOT.0b013e328355a992","article-title":"Regulatory T-cell therapy for transplantation: how many cells do we need","volume":"17","author":"Tang","year":"2012","journal-title":"Curr Opin Organ Transplant"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12433","article-title":"Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation","volume":"13","author":"Putnam","year":"2013","journal-title":"Am J Transplant"},{"key":"B63","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/14712598.2022.2026921","article-title":"Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from lupus","volume":"22","author":"Radic","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2014.11.005","article-title":"Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease","volume":"17","author":"Theil","year":"2015","journal-title":"Cytotherapy"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-027409","article-title":"Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion","volume":"108","author":"Hoffmann","year":"2006","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2016.10.011","article-title":"Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials","volume":"19","author":"McKenna","year":"2017","journal-title":"Cytotherapy"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.12.007","article-title":"Toward precision manufacturing of immunogene T-cell therapies","volume":"20","author":"Xu","year":"2018","journal-title":"Cytotherapy"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201747407","article-title":"An optimized method to measure human FOXP3(+) regulatory T cells from multiple tissue types using mass cytometry","volume":"48","author":"Dawson","year":"2018","journal-title":"Eur J Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23887","article-title":"Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the treg viability and phenotype","volume":"9","author":"Go\u0142\u0105b","year":"2018","journal-title":"Oncotarget"},{"key":"B70","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","article-title":"A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials","volume":"8","author":"Fraser","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00150","article-title":"Industrializing autologous adoptive immunotherapies: Manufacturing advances and challenges","volume":"5","author":"Iyer","year":"2018","journal-title":"Front Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001757","article-title":"Harnessing advances in T regulatory cell biology for cellular therapy in transplantation","volume":"101","author":"Lam","year":"2017","journal-title":"Transplantation"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-603449","article-title":"Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo","volume":"125","author":"Parmar","year":"2015","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14747","article-title":"Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs","volume":"18","author":"Sicard","year":"2018","journal-title":"Am J Transplant"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01460","article-title":"Engineered tolerance: Tailoring development, function, and antigen-specificity of regulatory T cells","volume":"8","author":"Dawson","year":"2017","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"108409","DOI":"10.1016\/j.intimp.2021.108409","article-title":"CAR treg: A new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686439","article-title":"Precision engineering of an anti-HLA-A2 chimeric antigen receptor in regulatory T cells for transplant immune tolerance","volume":"12","author":"Muller","year":"2021","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4+ CD25highCD127-regulatory T cells prolongs survival of pancreatic islets\u2013results of one year follow-up","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-016-1090-7","article-title":"Factors affecting long-term efficacy of T regulatory cell-based therapy in type 1 diabetes","volume":"14","author":"Marek-Trzonkowska","year":"2016","journal-title":"J Trans Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28459","article-title":"A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation","volume":"64","author":"Todo","year":"2016","journal-title":"Hepatology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001192","article-title":"Characterization and expansion of autologous GMP-ready regulatory T cells for TREG-based cell therapy in patients with ulcerative colitis","volume":"23","author":"Voskens","year":"2017","journal-title":"Inflammatory Bowel Dis"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory crohn\u2019s disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.147474","article-title":"The effect of low-dose IL-2 and treg adoptive cell therapy in patients with type 1 diabetes","volume":"6","author":"Dong","year":"2021","journal-title":"JCI Insight"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.28092","article-title":"Decreased number and impaired function of type 1 regulatory T cells in autoimmune diseases","volume":"234","author":"Jia","year":"2019","journal-title":"J Cell Physiol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1182\/blood-2004-01-0086","article-title":"Large-Scale in vitro expansion of polyclonal human CD4+ CD25high regulatory T cells","volume":"104","author":"Hoffmann","year":"2004","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001809","article-title":"Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity","volume":"3","author":"Hippen","year":"2011","journal-title":"Sci Trans Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"109494","DOI":"10.1016\/j.celrep.2021.109494","article-title":"Optimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human treg identity","volume":"36","author":"Lam","year":"2021","journal-title":"Cell Rep"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e0148474","DOI":"10.1371\/journal.pone.0148474","article-title":"Comparative analysis of protocols to induce human CD4+ Foxp3+ regulatory T cells by combinations of IL-2, TGF-beta, retinoic acid, rapamycin and butyrate","volume":"11","author":"Schmidt","year":"2016","journal-title":"PloS One"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401145","article-title":"Ex vivo\u2013expanded but not in vitro\u2013induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell\u2013specific demethylated region","volume":"194","author":"Rossetti","year":"2015","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"104733","DOI":"10.18632\/oncotarget.10914","article-title":"Combination of IL-2, rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells","volume":"8","author":"Miyara","year":"2017","journal-title":"Oncotarget"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714535","article-title":"miR-146b antagomir\u2013treated human tregs acquire increased GVHD inhibitory potency","volume":"128","author":"Lu","year":"2016","journal-title":"J Am Soc Hematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4375","article-title":"D-mannose induces regulatory T cells and suppresses immunopathology","volume":"23","author":"Zhang","year":"2017","journal-title":"Nat Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.01.002","article-title":"Induction of regulatory T cells: a role for probiotics and prebiotics to suppress autoimmunity","volume":"15","author":"Dwivedi","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783282","article-title":"IL-6 and TNF\u03b1 drive extensive proliferation of human tregs without compromising their lineage stability or function","volume":"12","author":"Skartsis","year":"2021","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.10.015","article-title":"Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier","volume":"142","author":"Esensten","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e6031","DOI":"10.1371\/journal.pone.0006031","article-title":"Suppression of glomerulonephritis in NZB\/NZW lupus prone mice by adoptive transfer of ex vivo expanded regulatory T cells","volume":"4","author":"Scalapino","year":"2009","journal-title":"PloS One"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903158107","article-title":"Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus","volume":"107","author":"Humrich","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/art.40014","article-title":"Brief report: CD4+ T cells from patients with systemic lupus erythematosus respond poorly to exogenous interleukin-2","volume":"69","author":"Comte","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12991","article-title":"Two separate effects contribute to regulatory T cell defect in systemic lupus erythematosus patients and their unaffected relatives","volume":"189","author":"Costa","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.3.1451","article-title":"Suppression of disease in new Zealand Black\/New Zealand white lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells","volume":"177","author":"Scalapino","year":"2006","journal-title":"J Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12029","article-title":"Clinical application of regulatory T cells in type 1 diabetes","volume":"14","author":"Marek-Trzonkowska","year":"2013","journal-title":"Pediatr Diabetes"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127244","article-title":"Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients","volume":"4","author":"Meyer","year":"2019","journal-title":"JCI Insight"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxx060","article-title":"Generation of allo-antigen-specific induced treg stabilized by vitamin c treatment and its application for prevention of acute graft versus host disease model","volume":"29","author":"Kasahara","year":"2017","journal-title":"Int Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008895","article-title":"In vivo\u2013generated antigen-specific regulatory T cells treat autoimmunity without compromising antibacterial immune response","volume":"6","author":"Kasagi","year":"2014","journal-title":"Sci Trans Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-017-0704-4","article-title":"Adoptive induced antigen-specific treg cells reverse inflammation in collagen-induced arthritis mouse model","volume":"41","author":"Sun","year":"2018","journal-title":"Inflammation"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaut.2017.01.001","article-title":"Generation of human islet-specific regulatory T cells by TCR gene transfer","volume":"79","author":"Hull","year":"2017","journal-title":"J Autoimmun"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e11726","DOI":"10.1371\/journal.pone.0011726","article-title":"Human antigen-specific regulatory T cells generated by T cell receptor gene transfer","volume":"5","author":"Brusko","year":"2010","journal-title":"PloS One"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-26161-6","article-title":"Treatment of T1D via optimized expansion of antigen-specific tregs induced by IL-2\/anti-IL-2 monoclonal antibody complexes and peptide\/MHC tetramers","volume":"8","author":"Izquierdo","year":"2018","journal-title":"Sci Rep"},{"key":"B112","article-title":"Ex vivo expansion of antigen-specific CD4+ CD25+ regulatory T cells from autologous na\u00efve CD4+ T cells of multiple sclerosis patients as a potential therapeutic approach","volume":"20","author":"Xiang","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3579","article-title":"Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes","volume":"105","author":"Mekala","year":"2005","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0505445102","article-title":"IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes","volume":"102","author":"Mekala","year":"2005","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transplant"},{"key":"B117","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B118","doi-asserted-by":"publisher","first-page":"101417","DOI":"10.1016\/j.molmet.2021.101417","article-title":"Modeling human T1D-associated autoimmune processes","volume":"56","author":"Khosravi-Maharlooei","year":"2021","journal-title":"Mol Metab"},{"key":"B119","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/jir.2017.0101","article-title":"IL-2 and beyond in cancer immunotherapy","volume":"38","author":"Wrangle","year":"2018","journal-title":"J Interferon Cytokine Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89278","article-title":"Low-dose IL-2 selectively activates subsets of CD4+ tregs and NK cells","volume":"1","author":"Hirakawa","year":"2016","journal-title":"JCI Insight"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aat1482","article-title":"Revisiting IL-2: Biology and therapeutic prospects","volume":"3","author":"Abbas","year":"2018","journal-title":"Sci Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.01.042","article-title":"Fine tuning subsets of CD4+ T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases","volume":"56","author":"Zhao","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0669","article-title":"\u03b2-Cell\u2013specific IL-2 therapy increases islet Foxp3+ treg and suppresses type 1 diabetes in NOD mice","volume":"62","author":"Johnson","year":"2013","journal-title":"Diabetes"},{"key":"B125","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J Autoimmun"},{"key":"B126","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"e1002139","DOI":"10.1371\/journal.pmed.1002139","article-title":"Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial","volume":"13","author":"Todd","year":"2016","journal-title":"PloS Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease","volume":"128","author":"Koreth","year":"2016","journal-title":"J Am Soc Hematol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity","volume":"20","author":"Kennedy-Nasser","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann Rheumatic Dis"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206506","article-title":"Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE","volume":"74","author":"Humrich","year":"2015","journal-title":"Ann Rheumatic Dis"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-017-8904-4","article-title":"Analysis of FOXP3+ regulatory T cell subpopulations in peripheral blood and tissue of patients with systemic lupus erythematosus","volume":"65","author":"Schmidt","year":"2017","journal-title":"Immunol Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary sj\u00f6gren\u2019s syndrome","volume":"77","author":"Miao","year":"2018","journal-title":"Ann Rheumatic Dis"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.017","article-title":"A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease","volume":"95","author":"Peterson","year":"2018","journal-title":"J Autoimmun"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1716173114","article-title":"Twenty-five years of mTOR: Uncovering the link from nutrients to growth","volume":"114","author":"Sabatini","year":"2017","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3077","article-title":"Control of PI(3) kinase in treg cells maintains homeostasis and lineage stability","volume":"16","author":"Huynh","year":"2015","journal-title":"Nat Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.04.014","article-title":"The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment","volume":"30","author":"Delgoffe","year":"2009","journal-title":"Immunity"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402540","article-title":"Combination therapy using IL-2\/IL-2 monoclonal antibody complexes, rapamycin, and islet autoantigen peptides increases regulatory T cell frequency and protects against spontaneous and induced type 1 diabetes in nonobese diabetic mice","volume":"195","author":"Manirarora","year":"2015","journal-title":"J Immunol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/gutjnl-2012-303635","article-title":"Autoimmune pancreatitis in MRL\/Mp mice is a T cell-mediated disease responsive to cyclosporine a and rapamycin treatment","volume":"63","author":"Schwaiger","year":"2014","journal-title":"Gut"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.18632\/aging.100925","article-title":"Rapamycin reverses the senescent phenotype and improves immuno-regulation of mesenchymal stem cells from MRL\/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway","volume":"8","author":"Gu","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/83713","article-title":"The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3","volume":"27","author":"Bennett","year":"2001","journal-title":"Nat Genet"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.jaci.2019.11.043","article-title":"Treatment with rapamycin can restore regulatory T-cell function in IPEX patients","volume":"145","author":"Passerini","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00151","article-title":"Restoring T cell tolerance, exploring the potential of histone deacetylase inhibitors for the treatment of juvenile idiopathic arthritis","volume":"10","author":"Nijhuis","year":"2019","journal-title":"Front Immunol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-09211-3","article-title":"Histone\/protein deacetylase 11 targeting promotes Foxp3+ treg function","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep"},{"key":"B149","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(13)70512-6","article-title":"Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1\/2 trial","volume":"15","author":"Choi","year":"2014","journal-title":"Lancet Oncol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-017-1357-2","article-title":"Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-l, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro","volume":"19","author":"Oh","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B151","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nri2234","article-title":"Evolving views on the genealogy of b cells","volume":"8","author":"Welner","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.2.705","article-title":"A case for regulatory b cells","volume":"176","author":"Mizoguchi","year":"2006","journal-title":"J Immunol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-009-0014-x","article-title":"Killer b lymphocytes: the evidence and the potential","volume":"58","author":"Lundy","year":"2009","journal-title":"Inflammation Res"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201040961","article-title":"What are regulatory b cells","volume":"40","author":"Gray","year":"2010","journal-title":"Eur J Immunol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1749-6632.2009.05137.x","article-title":"B10 cells and regulatory b cells balance immune responses during inflammation, autoimmunity, and cancer","volume":"1183","author":"DiLillo","year":"2010","journal-title":"Ann New York Acad Sci"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.11.009","article-title":"CD19+ CD24hiCD38hi b cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients","volume":"32","author":"Blair","year":"2010","journal-title":"Immunity"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294249","article-title":"Characterization of a rare IL-10\u2013competent b-cell subset in humans that parallels mouse regulatory B10 cells","volume":"117","author":"Iwata","year":"2011","journal-title":"J Am Soc Hematol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.03.017","article-title":"A regulatory b cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses","volume":"28","author":"Yanaba","year":"2008","journal-title":"Immunity"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.12.7868","article-title":"Novel suppressive function of transitional 2 b cells in experimental arthritis","volume":"178","author":"Evans","year":"2007","journal-title":"J Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902551","article-title":"Cutting edge: novel function of b cell-activating factor in the induction of IL-10\u2013producing regulatory b cells","volume":"184","author":"Yang","year":"2010","journal-title":"J Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2010.10.009","article-title":"Regulation of immunity and autoimmunity by b cells","volume":"22","author":"Mauri","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803052","article-title":"Selective targeting of b cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like b cells and for the suppression of lupus in MRL\/lpr mice","volume":"182","author":"Blair","year":"2009","journal-title":"J Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0700326104","article-title":"Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory b cells","volume":"104","author":"Gray","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100284","article-title":"Mice lacking endogenous IL-10\u2013producing regulatory b cells develop exacerbated disease and present with an increased frequency of Th1\/Th17 but a decrease in regulatory T cells","volume":"186","author":"Carter","year":"2011","journal-title":"J Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.11.009","article-title":"CD19 CD24 hi CD38 hi b cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients","volume":"32","author":"Mauri","year":"2010","journal-title":"Immunity"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.016","article-title":"Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation","volume":"41","author":"Matsumoto","year":"2014","journal-title":"Immunity"},{"key":"B167","doi-asserted-by":"publisher","first-page":"e49835","DOI":"10.1371\/journal.pone.0049835","article-title":"Decrease in proportion of CD19+ CD24(hi) CD27+ b cells and impairment of their suppressive function in graves\u2019 disease","volume":"7","author":"Zha","year":"2012","journal-title":"PloS One"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005407","article-title":"CD19+ CD24hiCD38hi b cells maintain regulatory T cells while limiting TH1 and TH17 differentiation","volume":"5","author":"Flores-Borja","year":"2013","journal-title":"Sci Trans Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.01.014","article-title":"IgG4 production is confined to human IL-10\u2013producing regulatory b cells that suppress antigen-specific immune responses","volume":"131","author":"van de Veen","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaut.2015.02.004","article-title":"B-cells induce regulatory T cells through TGF-\u03b2\/IDO production in a CTLA-4 dependent manner","volume":"59","author":"Nouel","year":"2015","journal-title":"J Autoimmun"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.02.008","article-title":"Lipid-antigen presentation by CD1d+ b cells is essential for the maintenance of invariant natural killer T cells","volume":"36","author":"Bosma","year":"2012","journal-title":"Immunity"},{"key":"B172","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2013-02-482406","article-title":"Adenosine production by human b cells and b cell\u2013mediated suppression of activated T cells","volume":"122","author":"Saze","year":"2013","journal-title":"J Am Soc Hematol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/nature12979","article-title":"IL-35-producing b cells are critical regulators of immunity during autoimmune and infectious diseases","volume":"507","author":"Shen","year":"2014","journal-title":"Nature"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory b cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat Med"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1111\/all.14763","article-title":"Regulatory b cells, a to z","volume":"76","author":"Jansen","year":"2021","journal-title":"Allergy"},{"key":"B176","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/B978-0-12-824390-9.00021-9","article-title":"B regulatory cells in patients with autoimmune diseases: Pathogenic significance and therapeutic potential","author":"Mavropoulos","year":"2022","journal-title":"Trans Autoimmun: Elsevier"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2011.08.019","article-title":"Reduction in IL-10 producing b cells (Breg) in multiple sclerosis is accompanied by a reduced naive\/memory breg ratio during a relapse but not in remission","volume":"239","author":"Knippenberg","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jdermsci.2015.11.003","article-title":"IL-10-producing regulatory b cells are decreased in patients with psoriasis","volume":"81","author":"Hayashi","year":"2016","journal-title":"J Dermatol Sci"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/ni833","article-title":"B cells regulate autoimmunity by provision of IL-10","volume":"3","author":"Fillatreau","year":"2002","journal-title":"Nat Immunol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3736","article-title":"Interleukin-10 produced by b cells is crucial for the suppression of Th17\/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis","volume":"14","author":"Carter","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36030","article-title":"Regulatory b cells inhibit EAE initiation in mice while other b cells promote disease progression","volume":"118","author":"Matsushita","year":"2008","journal-title":"J Clin Invest"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.012","article-title":"A regulatory feedback between plasmacytoid dendritic cells and regulatory b cells is aberrant in systemic lupus erythematosus","volume":"44","author":"Menon","year":"2016","journal-title":"Immunity"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3680","article-title":"Regulatory b cells are induced by gut microbiota\u2013driven interleukin-1\u03b2 and interleukin-6 production","volume":"20","author":"Rosser","year":"2014","journal-title":"Nat Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1038\/nature11501","article-title":"Regulatory b cells control T-cell autoimmunity through IL-21-dependent cognate interactions","volume":"491","author":"Yoshizaki","year":"2012","journal-title":"Nature"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402029","article-title":"IFN-\u03b2 treatment requires b cells for efficacy in neuroautoimmunity","volume":"194","author":"Schubert","year":"2015","journal-title":"J Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2003","article-title":"A granulocyte-macrophage colony\u2013stimulating factor and interleukin-15 fusokine induces a regulatory b cell population with immune suppressive properties","volume":"15","author":"Rafei","year":"2009","journal-title":"Nat Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.12.7779","article-title":"TLR agonists selectively promote terminal plasma cell differentiation of b cell subsets specialized in thymus-independent responses","volume":"178","author":"Genestier","year":"2007","journal-title":"J Immunol"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1002\/art.10287","article-title":"CD154\u2013CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus","volume":"46","author":"Grammer","year":"2002","journal-title":"Arthritis Rheumatism: Off J Am Coll Rheumatol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21438","article-title":"Helminth infections associated with multiple sclerosis induce regulatory b cells","volume":"64","author":"Correale","year":"2008","journal-title":"Ann Neurol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.155","article-title":"Fingolimod treatment promotes regulatory phenotype and function of b cells","volume":"2","author":"Gr\u00fctzke","year":"2015","journal-title":"Ann Clin Trans Neurol"},{"key":"B191","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","article-title":"B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis","volume":"30","author":"Thompson","year":"2010","journal-title":"J Clin Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04012.x","article-title":"B cell repopulation after alemtuzumab induction\u2013transient increase in transitional b cells and long-term dominance of na\u00efve b cells","volume":"12","author":"Heidt","year":"2012","journal-title":"Am J Transplantation"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.3109\/03009742.2015.1126346","article-title":"Decreased IL-10+ regulatory b cells (Bregs) in lupus nephritis patients","volume":"45","author":"Heinemann","year":"2016","journal-title":"Scandinavian J Rheumatol"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1002\/art.38742","article-title":"Impaired suppressive capacity of activation-induced regulatory b cells in systemic lupus erythematosus","volume":"66","author":"Gao","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2014.55.5.1354","article-title":"Regulatory b cells are inversely associated with disease activity in rheumatoid arthritis","volume":"55","author":"Kim","year":"2014","journal-title":"Yonsei Med J"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13192","article-title":"Impaired function of CD 19+ CD 24hi CD 38hi regulatory b cells in patients with pemphigus","volume":"172","author":"Zhu","year":"2015","journal-title":"Br J Dermatol"},{"key":"B197","article-title":"Pemphigus: autoimmunity to epidermal cell adhesion molecules","volume":"11","author":"Amagai","year":"1996","journal-title":"Adv Dermatol"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein b cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Trans Med"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5760849","article-title":"Decreased Breg\/Th17 ratio improved the prognosis of patients with ulcerative colitis","volume":"2018","author":"Bing","year":"2018","journal-title":"Can J Gastroenterol Hepatol"},{"key":"B200","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/art.39437","article-title":"Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis","volume":"68","author":"Mavropoulos","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev331","article-title":"Decreased levels of regulatory b cells in patients with systemic sclerosis: association with autoantibody production and disease activity","volume":"55","author":"Matsushita","year":"2016","journal-title":"Rheumatology"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1639","article-title":"Interleukin-10+ regulatory b cells arise within antigen-experienced CD40+ b cells to maintain tolerance to islet autoantigens","volume":"64","author":"Kleffel","year":"2015","journal-title":"Diabetes"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1097\/01.MIB.0000437983.14544.d5","article-title":"Role of regulatory b cells in chronic intestinal inflammation: association with pathogenesis of crohn\u2019s disease","volume":"20","author":"Oka","year":"2014","journal-title":"Inflammatory Bowel Dis"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85113","article-title":"Human regulatory b cells in health and disease: therapeutic potential","volume":"127","author":"Mauri","year":"2017","journal-title":"J Clin Invest"},{"key":"B205","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/intimm\/dxv026","article-title":"Regulatory b cells in human inflammatory and autoimmune diseases: from mouse models to clinical research","volume":"27","author":"Miyagaki","year":"2015","journal-title":"Int Immunol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22921","article-title":"Use of rituximab in systemic lupus erythematosus: a single center experience over 14 years","volume":"69","author":"Aguiar","year":"2017","journal-title":"Arthritis Care Res"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020060834","article-title":"Anti-CD20 mAb-induced b cell apoptosis generates T cell regulation of experimental myeloperoxidase ANCA-associated vasculitis","volume":"32","author":"Gan","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00274-1","article-title":"Chronic intestinal inflammatory condition generates IL-10-producing regulatory b cell subset characterized by CD1d upregulation","volume":"16","author":"Mizoguchi","year":"2002","journal-title":"Immunity"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.10.5132","article-title":"Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice","volume":"75","author":"Steinman","year":"1978","journal-title":"Proc Natl Acad Sci"},{"key":"B211","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev.immunol.21.120601.141040","article-title":"Tolerogenic dendritic cells","volume":"21","author":"Steinman","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00274","article-title":"Regulatory dendritic cells: there is more than just immune activation","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front Immunol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.01.024","article-title":"Expression and function of immunoglobulin-like transcripts on tolerogenic dendritic cells","volume":"70","author":"Wu","year":"2009","journal-title":"Hum Immunol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2011.06.007","article-title":"Tolerogenic dendritic cells and their role in transplantation","volume":"23","author":"Ezzelarab","year":"2011","journal-title":"Semin Immunol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.12.001","article-title":"Dendritic cell subsets and type I diabetes: focus upon DC-based therapy","volume":"5","author":"Lo","year":"2006","journal-title":"Autoimmun Rev"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2012.12.001","article-title":"Generation of large numbers of highly purified dendritic cells from bone marrow progenitor cells after co-culture with syngeneic murine splenocytes","volume":"94","author":"Kalantari","year":"2013","journal-title":"Exp Mol Pathol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/nature06175","article-title":"Taking dendritic cells into medicine","volume":"449","author":"Steinman","year":"2007","journal-title":"Nature"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1038\/nri2132","article-title":"Tolerogenic dendritic cells and the quest for transplant tolerance","volume":"7","author":"Morelli","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2011.01015.x","article-title":"Dendritic cell control of tolerogenic responses","volume":"241","author":"Manicassamy","year":"2011","journal-title":"Immunol Rev"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.6.1693","article-title":"Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte\/macrophage colony-stimulating factor","volume":"176","author":"Inaba","year":"1992","journal-title":"J Exp Med"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.3109\/08820130009060870","article-title":"Simplified method to generate large quantities of dendritic cells suitable for clinical applications","volume":"29","author":"Goxe","year":"2000","journal-title":"Immunol Investigations"},{"key":"B223","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1084\/jem.180.1.83","article-title":"Proliferating dendritic cell progenitors in human blood","volume":"180","author":"Romani","year":"1994","journal-title":"J Exp Med"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-380995-7.00004-5","article-title":"How tolerogenic dendritic cells induce regulatory T cells","volume":"108","author":"Maldonado","year":"2010","journal-title":"Adv Immunol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1471-4906(01)01952-4","article-title":"Dendritic cells as a tool to induce anergic and regulatory T cells","volume":"22","author":"Jonuleit","year":"2001","journal-title":"Trends Immunol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.7.4312","article-title":"Regulatory activity of autocrine IL-10 on dendritic cell functions","volume":"166","author":"Corinti","year":"2001","journal-title":"J Immunol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805058105","article-title":"TGF-\u03b2 signaling in dendritic cells is a prerequisite for the control of autoimmune encephalomyelitis","volume":"105","author":"Laouar","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803345","article-title":"1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype","volume":"182","author":"Sz\u00e9les","year":"2009","journal-title":"J Immunol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"B230","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nri1256","article-title":"Dendritic cells: emerging pharmacological targets of immunosuppressive drugs","volume":"4","author":"Hackstein","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2003.12.008","article-title":"Pharmacological induction of tolerogenic dendritic cells and regulatory T cells","volume":"16","author":"Adorini","year":"2004","journal-title":"Semin Immunol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1002\/art.22655","article-title":"Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB","volume":"56","author":"Martin","year":"2007","journal-title":"Arthritis Rheumatism"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200839103","article-title":"Induction of treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1","volume":"39","author":"Unger","year":"2009","journal-title":"Eur J Immunol"},{"key":"B234","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-71029-5_10","article-title":"Use of rapamycin in the induction of tolerogenic dendritic cells","volume-title":"Handb Exp Pharmacol","author":"Fischer","year":"2009"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.2174\/156652312800099580","article-title":"Viral and non-viral methods to genetically modify dendritic cells","volume":"12","author":"Humbert","year":"2012","journal-title":"Curr Gene Ther"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1016\/s1387-2656(01)07032-6","article-title":"RNA Interference: mechanisms and applications","volume":"7","author":"Fjose","year":"2001","journal-title":"Biotechnol Annu Rev"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.3109\/08830180903281193","article-title":"Development of dendritic cell-based immunotherapy for autoimmunity","volume":"29","author":"Hilkens","year":"2010","journal-title":"Int Rev Immunol"},{"key":"B238","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.trim.2008.05.005","article-title":"CTLA4-ig-modified dendritic cells inhibit lymphocyte-mediated alloimmune responses and prolong the islet graft survival in mice","volume":"19","author":"Yang","year":"2008","journal-title":"Transplant Immunol"},{"key":"B239","doi-asserted-by":"publisher","first-page":"e11848","DOI":"10.1371\/journal.pone.0011848","article-title":"Dendritic cells transduced to express interleukin 4 reduce diabetes onset in both normoglycemic and prediabetic nonobese diabetic mice","volume":"5","author":"Ruffner","year":"2010","journal-title":"PloS One"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000161252.17163.31","article-title":"Dendritic cells genetically engineered with adenoviral vector encoding dnIKK2 induce the formation of potent CD4+ T-regulatory cells","volume":"79","author":"Tomasoni","year":"2005","journal-title":"Transplantation"},{"key":"B241","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-9-89","article-title":"Comparative study of clinical grade human tolerogenic dendritic cells","volume":"9","author":"Naranjo-G\u00f3mez","year":"2011","journal-title":"J Trans Med"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.11.011","article-title":"IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction\u2013a comparative study of human clinical-applicable DC","volume":"142","author":"Boks","year":"2012","journal-title":"Clin Immunol"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1038\/nri3477","article-title":"The role of dendritic cells in autoimmunity","volume":"13","author":"Ganguly","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082394","article-title":"Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity","volume":"206","author":"Ohnmacht","year":"2009","journal-title":"J Exp Med"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2007.07.018","article-title":"The role of the innate immune response in autoimmune disease","volume":"29","author":"Lang","year":"2007","journal-title":"J Autoimmun"},{"key":"B246","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nri702","article-title":"Cytokines and autoimmunity","volume":"2","author":"O\u2019Shea","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2008.04.009","article-title":"The consequences of apoptosis in autoimmunity","volume":"31","author":"Lleo","year":"2008","journal-title":"J Autoimmun"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3260","article-title":"How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy","volume":"19","author":"Schett","year":"2013","journal-title":"Nat Med"},{"key":"B249","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10208","article-title":"Intestinal homeostasis and its breakdown in inflammatory bowel disease","volume":"474","author":"Maloy","year":"2011","journal-title":"Nature"},{"key":"B250","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.MIB.0000195389.11645.ab","article-title":"Toll-like receptor-1,-2, and-6 polymorphisms influence disease extension in inflammatory bowel diseases","volume":"12","author":"Pierik","year":"2006","journal-title":"Inflammatory Bowel Dis"},{"key":"B251","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/35079107","article-title":"Association of NOD2 leucine-rich repeat variants with susceptibility to crohn\u2019s disease","volume":"411","author":"Hugot","year":"2001","journal-title":"Nature"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.02996.x","article-title":"Dexamethasone\/1\u03b1-25-dihydroxyvitamin D3-treated dendritic cells suppress colitis in the SCID T-cell transfer model","volume":"127","author":"Pedersen","year":"2009","journal-title":"Immunology"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02600.x","article-title":"Tolerogenic dendritic cells pulsed with enterobacterial extract suppress development of colitis in the severe combined immunodeficiency transfer model","volume":"121","author":"Pedersen","year":"2007","journal-title":"Immunology"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142098","article-title":"Human CD 1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to e scherichia coli","volume":"42","author":"Kassianos","year":"2012","journal-title":"Eur J Immunol"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242632","article-title":"Naturally occurring CD 1c+ human regulatory dendritic cells: Immunoregulators that are expanded in response to e","volume":"42","author":"Qian","year":"2012","journal-title":"Coli Infect Eur J Immunol"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803404","article-title":"Human liver dendritic cells promote T cell hyporesponsiveness","volume":"182","author":"Bamboat","year":"2009","journal-title":"J Immunol"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126383","article-title":"Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis","volume":"69","author":"Harry","year":"2010","journal-title":"Ann Rheumatic Dis"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12038","article-title":"Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now","volume":"172","author":"Hilkens","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B260","doi-asserted-by":"publisher","first-page":"104087","DOI":"10.1016\/j.cellimm.2020.104087","article-title":"Generation and functional assessment of nonhuman primate regulatory dendritic cells and their therapeutic efficacy in renal transplantation","volume":"351","author":"Thomson","year":"2020","journal-title":"Cell Immunol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype\u2013positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Trans Med"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv144","article-title":"Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory crohn\u2019s disease: a phase I study","volume":"9","author":"Jauregui-Amezaga","year":"2015","journal-title":"J Crohn\u2019s Colitis"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.16393","article-title":"Donor-derived regulatory dendritic cell infusion results in host cell cross-dressing and T cell subset changes in prospective living donor liver transplant recipients","volume":"21","author":"Macedo","year":"2021","journal-title":"Am J Transplantation"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208456","article-title":"Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis","volume":"76","author":"Bell","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1002\/art.22655","article-title":"Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-\u03baB","volume":"56","author":"Martin","year":"2007","journal-title":"Arthritis Rheumatism: Off J Am Coll Rheumatol"},{"key":"B267","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar4130","article-title":"Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis","volume":"15","author":"Thomas","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151654","article-title":"Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models","volume":"70","author":"Stoop","year":"2011","journal-title":"Ann Rheumatic Dis"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1002\/art.27756","article-title":"Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses","volume":"62","author":"Stoop","year":"2010","journal-title":"Arthritis Rheumatism"},{"key":"B270","first-page":"169","article-title":"Safety and preliminary evidence of efficacy in a phase I clinical trial of autologous tolerising dendritic cells exposed to citrullinated peptides (Rheumavax) in patients with rheumatoid arthritis","volume":"70","author":"Thomas","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3037","article-title":"The terminology issue for myeloid-derived suppressor cells","volume":"67","author":"Gabrilovich","year":"2007","journal-title":"Cancer Res"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B273","doi-asserted-by":"publisher","first-page":"12369","DOI":"10.18632\/oncotarget.3682","article-title":"Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer","volume":"6","author":"Dufait","year":"2015","journal-title":"Oncotarget"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.2174\/156652409787314499","article-title":"Monocyte dependent regulation of autoimmune inflammation","volume":"9","author":"Nicholson","year":"2009","journal-title":"Curr Mol Med"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-010-0309-9","article-title":"Involvement of CD11b+ GR-1 low cells in autoimmune disorder in MRL-fas lpr mouse","volume":"14","author":"Iwata","year":"2010","journal-title":"Clin Exp Nephrol"},{"key":"B276","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imm.12718","article-title":"Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease","volume":"151","author":"Wegner","year":"2017","journal-title":"Immunology"},{"key":"B277","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br J Cancer"},{"key":"B278","doi-asserted-by":"publisher","first-page":"294","DOI":"10.4049\/jimmunol.1101590","article-title":"The role of Gr1+ cells after anti-CD20 treatment in type 1 diabetes in nonobese diabetic mice","volume":"188","author":"Hu","year":"2012","journal-title":"J Immunol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1002\/art.39767","article-title":"Myeloid-derived suppressor cells induce the expansion of regulatory b cells and ameliorate autoimmunity in the sanroque mouse model of systemic lupus erythematosus","volume":"68","author":"Park","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.8.5228","article-title":"CD11b+ ly-6Chi suppressive monocytes in experimental autoimmune encephalomyelitis","volume":"179","author":"Zhu","year":"2007","journal-title":"J Immunol"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1111\/imcb.12042","article-title":"Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis","volume":"96","author":"Iacobaeus","year":"2018","journal-title":"Immunol Cell Biol"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168575","article-title":"Circulating ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease","volume":"113","author":"King","year":"2009","journal-title":"J Am Soc Hematol"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203535","article-title":"Myeloid-derived suppressor cells play crucial roles in the regulation of mouse collagen-induced arthritis","volume":"191","author":"Fujii","year":"2013","journal-title":"J Immunol"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3HI0613-340RR","article-title":"Immunosuppressive monocytes: possible homeostatic mechanism to restrain chronic intestinal inflammation","volume":"96","author":"Kurmaeva","year":"2014","journal-title":"J Leukocyte Biol"},{"key":"B285","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1053\/j.gastro.2008.06.032","article-title":"Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway","volume":"135","author":"Haile","year":"2008","journal-title":"Gastroenterology"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1007\/s00430-010-0151-4","article-title":"Subsets, expansion and activation of myeloid-derived suppressor cells","volume":"199","author":"Ribechini","year":"2010","journal-title":"Med Microbiol Immunol"},{"key":"B288","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.18632\/oncotarget.12278","article-title":"On the origin of myeloid-derived suppressor cells","volume":"8","author":"Millrud","year":"2017","journal-title":"Oncotarget"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00028","article-title":"Regulatory T cell-mediated control of autoantibody-induced inflammation","volume":"3","author":"Fujio","year":"2012","journal-title":"Front Immunol"},{"key":"B290","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/hep.27571","article-title":"Cyclic adenosine monophosphate\u2013responsive element modulator alpha overexpression impairs function of hepatic myeloid-derived suppressor cells and aggravates immune-mediated hepatitis in mice","volume":"61","author":"Hammerich","year":"2015","journal-title":"Hepatology"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215617","article-title":"Stat proteins and oncogenesis","volume":"109","author":"Bromberg","year":"2002","journal-title":"J Clin Invest"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201041069","article-title":"In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site","volume":"41","author":"Haverkamp","year":"2011","journal-title":"Eur J Immunol"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02499","article-title":"Reactive oxygen species as regulators of MDSC-mediated immune suppression","volume":"9","author":"Ohl","year":"2018","journal-title":"Front Immunol"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid cell-derived arginase in cancer immune response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Front Immunol"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23841","article-title":"Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgfb1 knockout mouse liver","volume":"52","author":"Cripps","year":"2010","journal-title":"Hepatology"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.240","article-title":"Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-\u03b21","volume":"182","author":"Li","year":"2009","journal-title":"J Immunol"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.1038\/nri1457","article-title":"IDO expression by dendritic cells: tolerance and tryptophan catabolism","volume":"4","author":"Mellor","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1299","article-title":"Gr-1+ CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host","volume":"66","author":"Huang","year":"2006","journal-title":"Cancer Res"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0237-5","article-title":"Myeloid-derived suppressor cells control b cell accumulation in the central nervous system during autoimmunity","volume":"19","author":"Knier","year":"2018","journal-title":"Nat Immunol"},{"key":"B301","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/TP.0b013e31823ffd39","article-title":"Myeloid-derived suppressor cells (MDSC) protect islet transplants via B7-H1 mediated enhancement of T regulatory cells","volume":"93","author":"Chou","year":"2012","journal-title":"Transplantation"},{"key":"B302","doi-asserted-by":"publisher","first-page":"e111815","DOI":"10.1371\/journal.pone.0111815","article-title":"Suppression of proteoglycan-induced autoimmune arthritis by myeloid-derived suppressor cells generated in vitro from murine bone marrow","volume":"9","author":"Kurk\u00f3","year":"2014","journal-title":"PloS One"},{"key":"B303","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444799","article-title":"Functional characterization of myeloid-derived suppressor cell subpopulations during the development of experimental arthritis","volume":"45","author":"Wang","year":"2015","journal-title":"Eur J Immunol"},{"key":"B304","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/art.39007","article-title":"Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice","volume":"67","author":"Nishimura","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091474","article-title":"Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function","volume":"207","author":"Sander","year":"2010","journal-title":"J Exp Med"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1002\/art.38259","article-title":"Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells","volume":"66","author":"Louren\u00e7o","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B307","doi-asserted-by":"publisher","DOI":"10.1002\/art.38048","article-title":"Gr-1(high) CD11b+ cells suppress b cell differentiation and lupus-like disease in lupus-prone male mice","volume":"65","author":"Trigunaite","year":"2013","journal-title":"Arthritis Rheumatism"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3A0415-158R","article-title":"Immunosuppressive CD11b+ Ly6Chi monocytes in pristane-induced lupus mouse model","volume":"99","author":"Ma","year":"2016","journal-title":"J Leukocyte Biol"},{"key":"B309","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8377","article-title":"Myeloid suppressor cells induced by retinal pigment epithelial cells inhibit autoreactive T-cell responses that lead to experimental autoimmune uveitis","volume":"53","author":"Tu","year":"2012","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"B310","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-287839","article-title":"Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1\u2013dependent mechanism that is up-regulated by interleukin-13","volume":"116","author":"Highfill","year":"2010","journal-title":"J Am Soc Hematol"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.1002\/stem.301","article-title":"Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells","volume":"28","author":"Zhou","year":"2010","journal-title":"Stem Cells"},{"key":"B312","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.4.1841","article-title":"Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells","volume":"174","author":"MacDonald","year":"2005","journal-title":"J Immunol"},{"key":"B313","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.immuni.2010.05.010","article-title":"Tumor-induced tolerance and immune suppression depend on the C\/EBP\u03b2 transcription factor","volume":"32","author":"Marigo","year":"2010","journal-title":"Immunity"},{"key":"B314","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000901","article-title":"Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells","volume":"185","author":"Lechner","year":"2010","journal-title":"J Immunol"},{"key":"B315","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2047-1440-1-15","article-title":"Generation of myeloid-derived suppressor cells using prostaglandin e 2","volume":"1","author":"Obermajer","year":"2012","journal-title":"Transplant Res"},{"key":"B316","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nature14189","article-title":"The biology of innate lymphoid cells","volume":"517","author":"Artis","year":"2015","journal-title":"Nature"},{"key":"B317","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.218","article-title":"Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases","volume":"13","author":"Shikhagaie","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B318","doi-asserted-by":"crossref","DOI":"10.1007\/82_2014_381","article-title":"Transcription factors controlling innate lymphoid cell fate decisions","volume-title":"Curr Top Microbiol Immunol","author":"Klose","year":"2014"},{"key":"B319","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.03.030","article-title":"Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages","volume":"157","author":"Klose","year":"2014","journal-title":"Cell"},{"key":"B320","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-020711-075053","article-title":"Innate lymphoid cells: emerging insights in development, lineage relationships, and function","volume":"30","author":"Spits","year":"2012","journal-title":"Annu Rev Immunol"},{"key":"B321","doi-asserted-by":"publisher","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells\u2013a proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B322","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.146","article-title":"Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR+ ILC3 in lesional skin and blood of psoriasis patients","volume":"134","author":"Teunissen","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B323","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101377","article-title":"Natural killer-22 cells in the synovial fluid of patients with rheumatoid arthritis are an innate source of interleukin 22 and tumor necrosis factor-\u03b1","volume":"38","author":"Ren","year":"2011","journal-title":"J Rheumatol"},{"key":"B324","doi-asserted-by":"publisher","DOI":"10.4110\/in.2013.13.6.240","article-title":"Increased lymphocyte infiltration in rheumatoid arthritis is correlated with an increase in LTi-like cells in synovial fluid","volume":"13","author":"Koo","year":"2013","journal-title":"Immune Netw"},{"key":"B325","doi-asserted-by":"publisher","DOI":"10.1002\/art.10410","article-title":"A subset of natural killer cells is greatly expanded within inflamed joints","volume":"46","author":"Dalbeth","year":"2002","journal-title":"Arthritis Rheumatism"},{"key":"B326","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.10.6418","article-title":"CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation","volume":"173","author":"Dalbeth","year":"2004","journal-title":"J Immunol"},{"key":"B327","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nri3349","article-title":"Innate lymphoid cells\u2013how did we miss them","volume":"13","author":"Walker","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B328","doi-asserted-by":"publisher","DOI":"10.1002\/art.39261","article-title":"Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid","volume":"67","author":"Leijten","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B329","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.05.002","article-title":"GM-CSF as a therapeutic target in inflammatory diseases","volume":"56","author":"van Nieuwenhuijze","year":"2013","journal-title":"Mol Immunol"},{"key":"B330","doi-asserted-by":"publisher","DOI":"10.1002\/art.39685","article-title":"Brief report: Secukinumab provides significant and sustained inhibition of joint structural damage in a phase III study of active psoriatic arthritis","volume":"68","author":"van der Heijde","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B331","doi-asserted-by":"publisher","first-page":"R182","DOI":"10.1186\/ar3507","article-title":"Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of sj\u00f6gren\u2019s syndrome","volume":"13","author":"Fava","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B332","doi-asserted-by":"publisher","DOI":"10.1186\/ar2617","article-title":"Blockade of lymphotoxin-beta receptor signaling reduces aspects of sj\u00f6gren\u2019s syndrome in salivary glands of non-obese diabetic mice","volume":"11","author":"Gatumu","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"B333","doi-asserted-by":"publisher","DOI":"10.1038\/ni1330","article-title":"Lymphoid organ development: from ontogeny to neogenesis","volume":"7","author":"Drayton","year":"2006","journal-title":"Nat Immunol"},{"key":"B334","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.115","article-title":"A role for the lymphotoxin\/LIGHT axis in the pathogenesis of murine collagen-induced arthritis","volume":"171","author":"Fava","year":"2003","journal-title":"J Immunol"},{"key":"B335","doi-asserted-by":"publisher","first-page":"145ra06","DOI":"10.1126\/scitranslmed.3004140","article-title":"Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis","volume":"4","author":"Perry","year":"2012","journal-title":"Sci Transl Med"},{"key":"B336","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0282-9","article-title":"Plasticity of innate lymphoid cell subsets","volume":"20","author":"Bal","year":"2020","journal-title":"Nat Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1075813\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T15:09:35Z","timestamp":1679065775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1075813\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":336,"alternative-id":["10.3389\/fimmu.2022.1075813"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1075813","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"article-number":"1075813"}}